Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIVE trial of plant-derived recombinant human serum albumin after successful reperfusion in large-core acute ischemic stroke
ChiCTR2600132496Phase 2Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of recombinant human serum albumin in ischemic stroke (2 arms), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Early neurological deterioration by day 5-7 or discharge if earlier, All-cause mortality at 90 ±7 days and 2 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
recombinant human serum albumin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600132496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132496.